Introduction:
Still’s Disease is characterized by systemic inflammation, recurrent
fevers, and arthritis. It poses significant challenges in management,
particularly when complications such as hepatitis arise. Initial
treatment often involves IL-6 receptor inhibition with Tocilizumab, as
supported by clinical trials [1] and the use of rituximab as an
alternative [2]. We present a complex case where these therapies
were employed sequentially with varying outcomes.